CTLA4 Gene Complete Identifier and Functional Mapping Reference
Provide a comprehensive cross-database identifier and functional mapping reference for human CTLA4. This should serve as a definitive lookup resource …
Provide a comprehensive cross-database identifier and functional mapping reference for human CTLA4. This should serve as a definitive lookup resource for researchers. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 1: GENE IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Provide ALL gene-level database identifiers: - HGNC ID and approved symbol - Ensembl gene ID (ENSG) - NCBI Entrez Gene ID - OMIM gene/locus ID - Genomic location: chromosome, start position, end position, strand ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 2: TRANSCRIPT IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ List ALL transcript-level identifiers: - Ensembl transcripts: ALL ENST IDs with biotype (protein_coding, etc.) How many total transcripts? - RefSeq transcripts: ALL NM_ mRNA accessions Mark which is MANE Select (canonical clinical standard) - CCDS IDs: ALL consensus coding sequence identifiers For the CANONICAL/MANE SELECT transcript: - List ALL exon IDs (ENSE) with genomic coordinates - Total exon count ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 3: PROTEIN IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ List ALL protein-level identifiers: - UniProt accessions: ALL entries (reviewed and unreviewed) Mark the canonical reviewed entry - RefSeq protein: ALL NP_ accessions Protein domains and families: - List ALL annotated domains/families with identifiers - Include: domain name, type (domain/family/superfamily), and ID ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 4: STRUCTURE IDENTIFIERS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Experimental structures: - List ALL PDB structure IDs - For each: experimental method (X-ray, NMR, Cryo-EM) and resolution - Total PDB structure count Predicted structures: - AlphaFold model ID and confidence metrics (pLDDT) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 5: CROSS-SPECIES ORTHOLOGS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ List orthologous genes in key model organisms (where available): - Mouse (Mus musculus): gene ID, symbol - Rat (Rattus norvegicus): gene ID, symbol - Zebrafish (Danio rerio): gene ID, symbol - Fruit fly (Drosophila melanogaster): gene ID, symbol - Worm (C. elegans): gene ID, symbol - Yeast (S. cerevisiae): gene ID, symbol ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 6: CLINICAL VARIANTS & AI PREDICTIONS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Clinical variant annotations: - Total variant count in clinical databases - Breakdown by classification: Pathogenic, Likely Pathogenic, Uncertain Significance (VUS), Likely Benign, Benign - List TOP 50 pathogenic/likely pathogenic variants with: variant ID, HGVS notation, associated condition AI-based variant effect predictions: - Splice effect predictions: Total count List TOP 50 predicted splice-altering variants with delta scores - Missense pathogenicity predictions: Total count List TOP 50 predicted pathogenic missense variants with scores ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 7: BIOLOGICAL PATHWAYS & GENE ONTOLOGY ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Pathway membership: - List ALL biological pathways this gene participates in - Include pathway IDs and names - Total pathway count Gene Ontology annotations: - Biological Process: count and TOP 20 terms with IDs - Molecular Function: count and TOP 20 terms with IDs - Cellular Component: count and TOP 20 terms with IDs ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 8: PROTEIN INTERACTIONS & MOLECULAR NETWORKS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Protein-protein interactions: - Total interaction count - List TOP 50 highest-confidence interacting proteins with scores Protein similarity (evolutionary and structural): - Structural/embedding similarity: How many similar proteins? List TOP 20 with similarity scores - Sequence homology: How many homologous proteins? List TOP 20 with identity/similarity scores ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 9: TRANSCRIPTION FACTOR REGULATORY DATA ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ If this gene encodes a transcription factor: Downstream targets (genes regulated BY this TF): - Total target gene count - List TOP 50 target genes with regulation type (activates/represses) DNA binding profiles: - List ALL known binding motif IDs - Motif family classification Upstream regulators (TFs that regulate THIS gene): - List known transcriptional regulators with evidence type ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 10: DRUG & PHARMACOLOGY DATA ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ If this gene/protein is a drug target: Targeting molecules: - How many drug/compound molecules target this protein? - List TOP 30 molecules by development phase - Include: molecule ID, name, mechanism, highest development phase Clinical trials: - How many clinical trials involve drugs targeting this gene? - List TOP 20 trials with: trial ID, phase, status, intervention Pharmacogenomics: - Known drug-gene interactions affecting drug response - Dosing guidelines if any exist ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 11: EXPRESSION PROFILES ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Tissue expression: - Which tissues express this gene most highly? - List TOP 30 tissues with expression scores/levels - Note any tissue-specific or tissue-enriched patterns Cell type expression: - Which cell types show highest expression? - List TOP 30 cell types with expression scores - Note any cell type-specific patterns Single-cell expression data (if available): - Which single-cell datasets/experiments include this gene? - Notable cell population patterns ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 12: DISEASE ASSOCIATIONS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Mendelian/monogenic disease links: - What diseases are caused by mutations in this gene? - List ALL associated diseases with: disease name, disease ID, inheritance pattern, evidence level Phenotype associations: - What clinical phenotypes are associated with this gene? - List TOP 50 phenotype terms with IDs Complex trait associations (GWAS): - What traits/diseases are linked via genome-wide association studies? - List TOP 30 GWAS associations with: trait, study ID, p-value, effect size if available ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ FORMATTING REQUIREMENTS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ - Present each section with clear headers - Use tables for listing multiple items - Always include COUNTS for every category - For lists with >50 items: show total count + TOP 50 - For lists with <50 items: show ALL items - Always include database identifiers (IDs), not just names - Mark canonical/primary/reviewed entries where applicable - If a section has no data available, state "No data available" rather than omitting the section
Structured Data Sources
This answer was generated using Claude Opus 4.5 + BioBTree MCP, querying 37 biological databases.
Further analyze this answer or run your own queries with BioBTree MCP.
alphafold, alphamissense, bgee, biogrid_interaction, ccds, chembl_molecule, chembl_target, cl, clinvar, collectri, diamond_similarity, ensembl, entrez, esm2_similarity, exon, gencc, go, gwas, hgnc, hpo, intact, interpro, mim, orphanet, ortholog, pdb, pharmgkb, pharmgkb_gene, reactome, refseq, scxa, signor, spliceai, string_interaction, transcript, uberon, uniprotView API calls (56)
- search(CTLA4) https://sugi.bio/biobtree/api/search?i=CTLA4
- search(CTLA4, hgnc) https://sugi.bio/biobtree/api/search?i=CTLA4&s=hgnc
- search(CTLA4, ensembl) https://sugi.bio/biobtree/api/search?i=CTLA4&s=ensembl
- entry(HGNC:2505, hgnc) https://sugi.bio/biobtree/api/entry?i=HGNC%3A2505&s=hgnc
- entry(ENSG00000163599, ensembl) https://sugi.bio/biobtree/api/entry?i=ENSG00000163599&s=ensembl
- entry(1493, entrez) https://sugi.bio/biobtree/api/entry?i=1493&s=entrez
- map(HGNC:2505, >>hgnc>>ensembl) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Eensembl
- map(HGNC:2505, >>hgnc>>uniprot) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Euniprot
- map(HGNC:2505, >>hgnc>>mim) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Emim
- map(HGNC:2505, >>hgnc>>entrez) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Eentrez
- map(HGNC:2505, >>hgnc>>refseq) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Erefseq
- map(ENSG00000163599, >>ensembl>>transcript) https://sugi.bio/biobtree/api/map?i=ENSG00000163599&m=%3E%3Eensembl%3E%3Etranscript
- map(ENSG00000163599, >>ensembl>>uniprot) https://sugi.bio/biobtree/api/map?i=ENSG00000163599&m=%3E%3Eensembl%3E%3Euniprot
- map(HGNC:2505, >>hgnc>>ccds) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Eccds
- entry(P16410, uniprot) https://sugi.bio/biobtree/api/entry?i=P16410&s=uniprot
- entry(123890, mim) https://sugi.bio/biobtree/api/entry?i=123890&s=mim
- entry(ENST00000648405, transcript) https://sugi.bio/biobtree/api/entry?i=ENST00000648405&s=transcript
- map(ENST00000648405, >>transcript>>exon) https://sugi.bio/biobtree/api/map?i=ENST00000648405&m=%3E%3Etranscript%3E%3Eexon
- map(P16410, >>uniprot>>interpro) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Einterpro
- map(P16410, >>uniprot>>pdb) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Epdb
- map(P16410, >>uniprot>>alphafold) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Ealphafold
- map(ENSG00000163599, >>ensembl>>ortholog) https://sugi.bio/biobtree/api/map?i=ENSG00000163599&m=%3E%3Eensembl%3E%3Eortholog
- map(HGNC:2505, >>hgnc>>clinvar) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Eclinvar
- map(P16410, >>uniprot>>go) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Ego
- map(P16410, >>uniprot>>reactome) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Ereactome
- map(HGNC:2505, >>hgnc>>spliceai) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Espliceai
- entry(ENSMUSG00000026011, ensembl) https://sugi.bio/biobtree/api/entry?i=ENSMUSG00000026011&s=ensembl
- entry(ENSRNOG00000054129, ensembl) https://sugi.bio/biobtree/api/entry?i=ENSRNOG00000054129&s=ensembl
- map(P16410, >>uniprot>>string_interaction) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Estring_interaction
- map(P16410, >>uniprot>>intact) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Eintact
- map(P16410, >>uniprot>>biogrid_interaction) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Ebiogrid_interaction
- map(P16410, >>uniprot>>alphamissense) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Ealphamissense
- map(HGNC:2505, >>hgnc>>gwas) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Egwas
- map(HGNC:2505, >>hgnc>>hpo) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Ehpo
- map(HGNC:2505, >>hgnc>>gencc) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Egencc
- map(HGNC:2505, >>hgnc>>orphanet) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Eorphanet
- map(P16410, >>uniprot>>esm2_similarity) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Eesm2_similarity
- map(P16410, >>uniprot>>diamond_similarity) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Ediamond_similarity
- map(HGNC:2505, >>hgnc>>collectri) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Ecollectri
- map(P16410, >>uniprot>>chembl_target) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Echembl_target
- map(ENSG00000163599, >>ensembl>>bgee) https://sugi.bio/biobtree/api/map?i=ENSG00000163599&m=%3E%3Eensembl%3E%3Ebgee
- map(CHEMBL2364164, >>chembl_target>>chembl_molecule) https://sugi.bio/biobtree/api/map?i=CHEMBL2364164&m=%3E%3Echembl_target%3E%3Echembl_molecule
- map(ENSG00000163599, >>ensembl>>bgee>>uberon) https://sugi.bio/biobtree/api/map?i=ENSG00000163599&m=%3E%3Eensembl%3E%3Ebgee%3E%3Euberon
- map(ENSG00000163599, >>ensembl>>bgee>>cl) https://sugi.bio/biobtree/api/map?i=ENSG00000163599&m=%3E%3Eensembl%3E%3Ebgee%3E%3Ecl
- map(HGNC:2505, >>hgnc>>pharmgkb_gene) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Epharmgkb_gene
- map(P16410, >>uniprot>>signor) https://sugi.bio/biobtree/api/map?i=P16410&m=%3E%3Euniprot%3E%3Esignor
- search(ipilimumab) https://sugi.bio/biobtree/api/search?i=ipilimumab
- search(tremelimumab) https://sugi.bio/biobtree/api/search?i=tremelimumab
- search(abatacept) https://sugi.bio/biobtree/api/search?i=abatacept
- map(PA27006, >>pharmgkb_gene>>pharmgkb) https://sugi.bio/biobtree/api/map?i=PA27006&m=%3E%3Epharmgkb_gene%3E%3Epharmgkb
- map(ENSG00000163599, >>ensembl>>scxa) https://sugi.bio/biobtree/api/map?i=ENSG00000163599&m=%3E%3Eensembl%3E%3Escxa
- entry(CHEMBL1789844, chembl_molecule) https://sugi.bio/biobtree/api/entry?i=CHEMBL1789844&s=chembl_molecule
- entry(CHEMBL2108658, chembl_molecule) https://sugi.bio/biobtree/api/entry?i=CHEMBL2108658&s=chembl_molecule
- entry(CHEMBL1201823, chembl_molecule) https://sugi.bio/biobtree/api/entry?i=CHEMBL1201823&s=chembl_molecule
- map(HGNC:2505, >>hgnc>>clinvar) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Eclinvar
- map(HGNC:2505, >>hgnc>>hpo) https://sugi.bio/biobtree/api/map?i=HGNC%3A2505&m=%3E%3Ehgnc%3E%3Ehpo
CTLA4 - Comprehensive Cross-Database Identifier and Functional Mapping Reference ╔═══════════════════════════════════════════════════════════════════════════════╗ ║ CTLA4 ║ ║ Cytotoxic T-Lymphocyte Associated Protein 4 (CD152) ║ ╚═══════════════════════════════════════════════════════════════════════════════╝
Section 1: Gene Identifiers
| Database | Identifier | Notes |
|---|---|---|
| HGNC ID | HGNC:2505 | Approved |
| Approved Symbol | CTLA4 | |
| Approved Name | cytotoxic T-lymphocyte associated protein 4 | |
| Ensembl Gene | ENSG00000163599 | |
| NCBI Entrez Gene | 1493 | |
| OMIM | 123890 | Gene/locus |
| RefSeq Gene | 1493 |
| Attribute | Value |
|---|---|
| Chromosome | 2 |
| Cytogenetic Band | 2q33.2 |
| Start Position | 203,853,888 |
| End Position | 203,873,965 |
| Strand | + (forward) |
| Genome Assembly | GRCh38 |
| Genomic Accession | NC_000002.12 |
Section 2: Transcript Identifiers Ensembl Transcripts (Total: 7)
| Transcript ID | Biotype | Start | End | Strand | UTR5 | UTR3 |
|---|---|---|---|---|---|---|
| ENST00000648405 | protein_coding | 203,867,771 | 203,873,965 | + | 203,867,771-203,867,942 | 203,872,813-203,873,965 |
| ENST00000696479 | protein_coding | 203,853,888 | 203,873,965 | + | 203,853,888-203,854,029 | 203,872,813-203,873,965 |
| ENST00000696049 | protein_coding | 203,867,771 | 203,873,196 | + | 203,867,771-203,867,942 | 203,872,813-203,873,196 |
| ENST00000295854 | protein_coding | 203,867,943 | 203,872,775 | + | - | - |
| ENST00000487393 | protein_coding | 203,867,943 | 203,872,812 | + | - | 203,872,776-203,872,812 |
| ENST00000427473 | protein_coding_CDS_not_defined | 203,870,232 | 203,873,090 | + | - | - |
| ENST00000650075 | protein_coding_CDS_not_defined | 203,870,242 | 203,872,856 | + | - | - |
| Accession | Type | Status | Chromosome | MANE Select |
|---|---|---|---|---|
| NM_005214 | mRNA | REVIEWED | 2 | Yes (Canonical) |
| NM_001037631 | mRNA | REVIEWED | 2 | No |
| Accession | Type | Status | MANE Select |
|---|---|---|---|
| NP_005205 | protein | REVIEWED | Yes |
| NP_001032720 | protein | REVIEWED | No |
- CCDS2362
- CCDS42803 Exons for Canonical Transcript (ENST00000648405) - Total: 4
| Exon ID | Start | End | Strand |
|---|---|---|---|
| ENSE00003967479 | 203,867,771 | 203,868,051 | + |
| ENSE00003548810 | 203,870,586 | 203,870,933 | + |
| ENSE00003965893 | 203,871,378 | 203,871,487 | + |
| ENSE00003965892 | 203,872,708 | 203,873,965 | + |
Section 3: Protein Identifiers UniProt Accessions (Total: 3)
| Accession | Status | Name | Length | Mass |
|---|---|---|---|---|
| P16410 | Reviewed (Swiss-Prot) | Cytotoxic T-lymphocyte protein 4 | 223 aa | 24,656 Da |
| A0A8Q3SIR7 | Unreviewed (TrEMBL) | - | - | - |
| A0A8Q3WKZ2 | Unreviewed (TrEMBL) | - | - | - |
| InterPro ID | Name | Type |
|---|---|---|
| IPR008096 | CTLA4 | Family |
| IPR040216 | CTLA4/CD28 | Family |
| IPR013106 | Ig_V-set | Domain |
| IPR003599 | Ig_sub | Domain |
| IPR013783 | Ig-like_fold | Homologous_superfamily |
| IPR036179 | Ig-like_dom_sf | Homologous_superfamily |
Section 4: Structure Identifiers Experimental Structures (Total: 22 PDB entries)
| PDB ID | Method | Resolution | Title |
|---|---|---|---|
| 9DQ3 | X-ray | 1.64 Å | Engineered Ipilimumab (mipi.4) Fab + CTLA-4 |
| 3OSK | X-ray | 1.8 Å | CTLA-4 apo homodimer |
| 5GGV | X-ray | 2.0 Å | CTLA-4 + tremelimumab Fab |
| 3BX7 | X-ray | 2.1 Å | Lipocalin 2 + CTLA-4 extracellular domain |
| 7ELX | X-ray | 2.14 Å | CTLA-4 + Fab |
| 7DV4 | X-ray | 2.38 Å | Anti-CTLA-4 VH domain + CTLA-4 |
| 7SU0 | X-ray | 2.41 Å | Acidic pH-selective Ipilimumab variant + CTLA-4 |
| 7SU1 | X-ray | 2.53 Å | Acidic pH-selective Ipilimumab variant + CTLA-4 |
| 2X44 | X-ray | 2.6 Å | Strand-swapped dimeric CTLA-4 |
| 6RP8 | X-ray | 2.6 Å | Ipilimumab Fab + CTLA-4 |
| 8GAB | X-ray | 2.72 Å | CTLA-4 + high affinity binder |
| 1I8L | X-ray | 3.0 Å | B7-1/CTLA-4 co-stimulatory complex |
| 5TRU | X-ray | 3.0 Å | Ipilimumab + CTLA-4 |
| 6RQM | X-ray | 3.0 Å | Blocking anti-CTLA-4 Nanobody (KN044) + CTLA-4 |
| 6XY2 | X-ray | 3.05 Å | CTLA-4 + HL32 antibody Fab |
| 7CIO | X-ray | 1.1 Å | CTLA-4 cytoplasmic region + PI3K SH2 domains |
| 1I85 | X-ray | 3.2 Å | CTLA-4/B7-2 complex |
| 5XJ3 | X-ray | 3.2 Å | Ipilimumab-scFv + CTLA-4 |
| 8HIT | X-ray | 3.2 Å | Anti-CTLA-4 humanized IgG1 MAb JS007 + CTLA-4 |
| 6RPJ | X-ray | 3.25 Å | Non-blocking anti-CTLA-4 Nanobody + CTLA-4 |
| 1H6E | X-ray | 3.6 Å | AP50 + CTLA-4 internalization peptide |
| 1AH1 | NMR | - | CTLA-4, 20 structures |
| Database | ID | pLDDT (Global) | Sequence Length | Fraction Very High Confidence |
|---|---|---|---|---|
| AlphaFold | P16410 | 79.67 | 1728 | 0.48 (48%) |
Section 5: Cross-Species Orthologs
| Organism | Gene ID | Symbol | Chromosome | Biotype |
|---|---|---|---|---|
| Human (Homo sapiens) | ENSG00000163599 | CTLA4 | 2 | protein_coding |
| Mouse (Mus musculus) | ENSMUSG00000026011 | Ctla4 | 1 | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000054129 | Ctla4 | 9 | protein_coding |
| Zebrafish (Danio rerio) | No ortholog found | - | - | - |
| Fruit fly (D. melanogaster) | No ortholog found | - | - | - |
| Worm (C. elegans) | No ortholog found | - | - | - |
| Yeast (S. cerevisiae) | No ortholog found | - | - | - |
Section 6: Clinical Variants & AI Predictions ClinVar Variant Summary (Total: 285 variants)
| Classification | Count |
|---|---|
| Pathogenic | 22 |
| Likely Pathogenic | 16 |
| Pathogenic/Likely Pathogenic | 3 |
| Uncertain Significance (VUS) | 79 |
| Conflicting Classifications | 6 |
| Likely Benign | 63 |
| Benign | 19 |
| Variant ID | HGVS Notation | Classification | Review Status |
|---|---|---|---|
| 1029948 | c.226C>T (p.Gln76Ter) | Pathogenic | Multiple submitters |
| 161109 | c.151C>T (p.Arg51Ter) | Pathogenic | Expert panel |
| 161110 | c.75del (p.Leu28fs) | Pathogenic | Expert panel |
| 161112 | c.105C>A (p.Cys35Ter) | Pathogenic | Expert panel |
| 1439020 | c.71_72del (p.Leu24fs) | Pathogenic | Expert panel |
| 1449408 | c.238C>T (p.Gln80Ter) | Pathogenic | Single submitter |
| 2097298 | c.216dup (p.Val73fs) | Pathogenic | Single submitter |
| 2128011 | c.160G>C (p.Ala54Pro) | Pathogenic | Single submitter |
| 2151958 | c.450T>G (p.Tyr150Ter) | Pathogenic | Single submitter |
| 2151959 | c.494G>A (p.Trp165Ter) | Pathogenic | Single submitter |
| 2704586 | c.415T>C (p.Tyr139His) | Pathogenic | Single submitter |
| 3033903 | c.457+1G>A | Pathogenic | No criteria |
| 3384671 | c.346del (p.Ile116fs) | Pathogenic | No criteria |
| 3722056 | c.271dup (p.Met91fs) | Pathogenic | Single submitter |
| 3765360 | c.255_270dup (p.Met91fs) | Pathogenic | Single submitter |
| 4277914 | c.2T>C (p.Met1Thr) | Pathogenic | Single submitter |
| 161114 | c.208C>T (p.Arg70Trp) | Pathogenic/Likely pathogenic | Multiple submitters |
| 280759 | c.60G>A (p.Trp20Ter) | Pathogenic/Likely pathogenic | Multiple submitters |
| 161113 | c.109+1G>T | Likely pathogenic | Single submitter |
| 1472488 | c.416A>C (p.Tyr139Ser) | Likely pathogenic | Single submitter |
| 1711524 | c.407C>T (p.Pro136Leu) | Likely pathogenic | Expert panel |
| 1801487 | c.231_297delinsA (p.Gln80_Ser101del) | Likely pathogenic | Single submitter |
| 2431823 | c.381C>A (p.Tyr127Ter) | Likely pathogenic | Single submitter |
| 2760703 | c.110-1G>A | Likely pathogenic | Single submitter |
| 3340448 | c.173G>A (p.Cys58Tyr) | Likely pathogenic | Single submitter |
| 3384193 | c.529del (p.Tyr177fs) | Likely pathogenic | No criteria |
| 3384219 | c.221T>C (p.Leu74Pro) | Likely pathogenic | No criteria |
| 3600293 | c.401T>G (p.Met134Arg) | Likely pathogenic | No criteria |
| 3653881 | c.423_428dup (p.Gly142_Ile143insMetGly) | Likely pathogenic | Single submitter |
| 3704373 | c.178T>A (p.Tyr60Asn) | Likely pathogenic | Single submitter |
| 3905783 | c.519del (p.Leu174fs) | Likely pathogenic | Single submitter |
| 3906997 | c.412C>T (p.Pro138Ser) | Likely pathogenic | Single submitter |
| 432079 | c.410C>T (p.Pro137Leu) | Likely pathogenic | Expert panel |
| 1071971 | g.(?204731519)(204732794_?)del | Pathogenic | Single submitter |
| 2425320 | g.(?204734049)(204737535_?)del | Pathogenic | Single submitter |
| 187825 | 2q33.2-33.3 CNV loss | Likely pathogenic | Single submitter |
| Variant | Effect | Delta Score |
|---|---|---|
| 2:203868049:AAGGT>A | donor_loss | 1.00 |
| 2:203868052:G>C | donor_loss | 1.00 |
| 2:203870579:A>AG | acceptor_gain | 0.99 |
| 2:203870579:AT>A | acceptor_gain | 0.99 |
| 2:203870580:T>G | acceptor_gain | 0.99 |
| 2:203870580:T>TA | acceptor_gain | 0.99 |
| 2:203870584:A>AG | acceptor_gain | 0.99 |
| 2:203870585:G>GG | acceptor_gain | 0.99 |
| 2:203870585:G>GT | acceptor_loss | 0.98 |
| 2:203868053:T>G | donor_loss | 0.99 |
| 2:203868052:G>GG | donor_gain | 0.99 |
| 2:203870581:GCTA>G | acceptor_loss | 0.98 |
| 2:203870582:CTA>C | acceptor_loss | 0.98 |
| 2:203870583:TAG>T | acceptor_loss | 0.98 |
| 2:203870584:A>C | acceptor_loss | 0.98 |
| 2:203868049:AAG>A | donor_gain | 0.92 |
| 2:203868050:AG>A | donor_gain | 0.92 |
| 2:203868051:GG>G | donor_gain | 0.92 |
| 2:203868054:GAGT>G | donor_loss | 0.92 |
| 2:203867996:G>GT | donor_gain | 0.83 |
| 2:203868815:A>G | donor_gain | 0.82 |
| 2:203870583:TAGCA>T | acceptor_gain | 0.80 |
| 2:203870584:AGCAA>A | acceptor_gain | 0.80 |
| 2:203870569:T>TA | acceptor_gain | 0.76 |
| 2:203870580:TGCTA>T | acceptor_gain | 0.75 |
| 2:203870581:GCTAG>G | acceptor_gain | 0.75 |
| 2:203870582:CTAGC>C | acceptor_gain | 0.75 |
| 2:203868743:G>T | acceptor_gain | 0.73 |
| 2:203870570:G>A | acceptor_gain | 0.67 |
| 2:203868055:A>AG | donor_gain | 0.66 |
| 2:203868056:G>GG | donor_gain | 0.66 |
| 2:203868047:CAAAG>C | donor_gain | 0.64 |
| 2:203870012:AC>A | donor_gain | 0.60 |
| 2:203870070:G>GG | donor_gain | 0.62 |
| 2:203870066:C>CG | donor_gain | 0.59 |
| 2:203870069:A>AG | donor_gain | 0.59 |
| 2:203869996:G>T | donor_gain | 0.58 |
| 2:203868055:AGTG>A | donor_loss | 0.55 |
| 2:203868814:GA>G | donor_gain | 0.53 |
- Likely Benign: ~1,400 (majority in signal peptide region)
- Ambiguous: ~50
- Likely Pathogenic: ~10 TOP 50 Predicted Pathogenic Missense Variants (by highest pathogenicity score)
| Variant | Protein Change | Pathogenicity Score | Classification |
|---|---|---|---|
| 2:203867958:T>C | F6L | 0.407 | ambiguous |
| 2:203867960:T>A | F6L | 0.407 | ambiguous |
| 2:203867960:T>G | F6L | 0.407 | ambiguous |
Section 7: Biological Pathways & Gene Ontology Reactome Pathways (Total: 3)
| Pathway ID | Pathway Name | Disease Pathway |
|---|---|---|
| R-HSA-389513 | Co-inhibition by CTLA4 | No |
| R-HSA-389356 | Co-stimulation by CD28 | No |
| R-HSA-8877330 | RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | No |
| GO ID | Term Name |
|---|---|
| GO:0002250 | adaptive immune response |
| GO:0006955 | immune response |
| GO:0006974 | DNA damage response |
| GO:0030889 | negative regulation of B cell proliferation |
| GO:0042130 | negative regulation of T cell proliferation |
| GO:0043065 | positive regulation of apoptotic process |
| GO:0045590 | negative regulation of regulatory T cell differentiation |
| GO:0050852 | T cell receptor signaling pathway |
| GO:0050853 | B cell receptor signaling pathway |
| GO:0050860 | negative regulation of T cell receptor signaling pathway |
| GO:0050868 | negative regulation of T cell activation |
| GO ID | Term Name |
|---|---|
| GO:0140319 | receptor decoy activity |
| GO ID | Term Name |
|---|---|
| GO:0005794 | Golgi apparatus |
| GO:0005886 | plasma membrane |
| GO:0009897 | external side of plasma membrane |
| GO:0045334 | clathrin-coated endocytic vesicle |
| GO:0048471 | perinuclear region of cytoplasm |
| GO:0098636 | protein complex involved in cell adhesion |
Section 8: Protein Interactions & Molecular Networks Protein-Protein Interactions IntAct Interactions (Total: 53) TOP 50 Highest-Confidence Interacting Proteins
| Interacting Partner | Interaction Type | Confidence Score |
|---|---|---|
| CD80 (B7-1) | direct interaction | 0.880 |
| CD80 | physical association | 0.880 |
| CD86 (B7-2) | direct interaction | 0.840 |
| CD86 | physical association | 0.840 |
| LRBA | physical association | 0.670 |
| PIK3R1 | association | 0.640 |
| MALL | physical association | 0.560 |
| TMEM218 | physical association | 0.560 |
| CTXN3 | physical association | 0.560 |
| B4GALT5 | association | 0.530 |
| RAPGEF1 | physical association | 0.400 |
| CD274 (PD-L1) | physical association | 0.400 |
| SIGLEC10 | physical association | 0.400 |
| ICOSLG | physical association | 0.400 |
| TMEM120B | association | 0.350 |
| RAB8A | colocalization | 0.270 |
| TRIM25 | colocalization | 0.270 |
| LAX1 | colocalization | 0.270 |
| AKT1 | proximity | 0.270 |
| SMARCA4 | proximity | 0.270 |
| SPOP | proximity | 0.270 |
| EGFR | proximity | 0.270 |
| BRAF | proximity | 0.270 |
| FYN | proximity | 0.270 |
| STAT5B | proximity | 0.270 |
| STAT5A | proximity | 0.270 |
| UniProt B | Score |
|---|---|
| P33681 (CD28) | 999 |
| P42081 (CD86) | 999 |
| Q9BQ51 (PD-CD1LG2) | 999 |
| Q9NZQ7 (PD-1) | 999 |
| Q9Y6W8 (ICOS) | 994 |
| O75144 (ICOS-L) | 993 |
| P10747 (CD80) | 987 |
| Q06124 (PTPN11) | 984 |
| P25942 (CD40) | 973 |
| P18627 (LAG3) | 956 |
| Q7Z7D3 (TIGIT) | 953 |
| P15151 (PVR) | 950 |
| P01730 (CD4) | 948 |
| Q9BZS1 (FOXP3) | 947 |
| P01585 (IL2) | 937 |
| P01579 (IFNG) | 933 |
| P01732 (CD8A) | 931 |
| Q92692 (NECTIN2) | 931 |
| Q9Y5U5 (TNFRSF18/GITR) | 928 |
| Q5JR59 (BTLA) | 926 |
| Q9ULD2 (HAVCR2/TIM3) | 925 |
| P22301 (IL10) | 915 |
| P14902 (IDO1) | 901 |
| Partner | Experimental System |
|---|---|
| CD80 | Reconstituted Complex, Co-crystal Structure |
| CD86 | Co-crystal Structure |
| AP2M1 | Co-crystal Structure, Two-hybrid, Affinity Capture-Western |
| FYN | Affinity Capture-Western |
| LCK | Affinity Capture-Western |
| LYN | Affinity Capture-Western |
| PPP2R5A | Affinity Capture-Western, Two-hybrid |
| LRBA | Affinity Capture-MS |
| CTXN3 | Two-hybrid |
| UniProt | Similarity Score | Description |
|---|---|---|
| Q3TEW6 | 0.9999 | Mouse Ctla4 |
| Q6AYT8 | 0.9999 | Rat Ctla4 |
| P10966 | 0.9998 | CD28 (Bos taurus) |
| P30434 | 0.9998 | CD28 variant |
| Q16653 | 0.9997 | CD28 (human isoform) |
| Q50DM8 | 0.9997 | CD28 |
| Q9BGS7 | 0.9996 | CTLA4 (bovine) |
| A6NJW9 | 0.9996 | CTLA4 isoform |
| P31041 | 0.9991 | CD28 (mouse) |
| P31042 | 0.9991 | CD28 (rat) |
| Q9MYX7 | 0.9990 | CTLA4 (pig) |
| Q9XSI1 | 0.9990 | CTLA4 (sheep) |
| O02757 | 0.9988 | CTLA4 (rabbit) |
| P42069 | 0.9988 | CTLA4 (macaque) |
| O88875 | 0.9938 | CTLA4 (mouse) |
| P16410 | 0.9984 | CTLA4 (self) |
| P27930 | 0.9984 | ICOS |
| P42072 | 0.9985 | CTLA4 (dog) |
| Q28071 | 0.9985 | CTLA4 (cattle) |
| P09793 | 0.9974 | CD28 |
| UniProt | Top Identity (%) | Bitscore |
|---|---|---|
| P31041 (CD28 mouse) | 91.7% | 408 |
| Q9MYX7 (CTLA4 pig) | 90.1% | 408 |
| Q9XSI1 (CTLA4 sheep) | 90.1% | 409 |
| P42072 (CTLA4 dog) | 86.5% | 389 |
| P16410 (CTLA4 human) | 85.7% | 394 |
| O02757 (CTLA4 rabbit) | 83.3% | 382 |
| P42069 (CTLA4 macaque) | 83.3% | 382 |
| Q28071 (CTLA4 cattle) | 82.2% | 367 |
| P10747 (CD80 human) | 79.5% | 355 |
| P09793 (CD28) | 74.9% | 338 |
| P31043 | 53.8% | 212 |
Section 9: Transcription Factor Regulatory Data CTLA4 is NOT a transcription factor. It is a transmembrane receptor protein. Upstream Regulators (TFs that regulate CTLA4 expression) - Total: 15
| Transcription Factor | Regulation Type | Confidence |
|---|---|---|
| FOXP3 | Unknown | High |
| FOXO1 | Repression | High |
| NFATC2 | Unknown | High |
| AP1 | Unknown | High |
| AR | Unknown | High |
| ESR1 | Unknown | High |
| GATA3 | Unknown | High |
| IRF8 | Unknown | High |
| NR5A1 | Unknown | High |
| MSC | Activation | - |
| RUNX1 | Repression | - |
| NR3C1 | Unknown | - |
| LEF1 | Unknown | Low |
| USF1 | Unknown | Low |
| USF2 | Unknown | Low |
| Entity A | Entity B | Effect | Mechanism | Direct |
|---|---|---|---|---|
| FYN | CTLA4 | up-regulates quantity by stabilization | phosphorylation | Yes |
| JAK2 | CTLA4 | up-regulates quantity by stabilization | phosphorylation | Yes |
| LCK | CTLA4 | up-regulates quantity by stabilization | phosphorylation | Yes |
| TXK | CTLA4 | up-regulates quantity by stabilization | phosphorylation | Yes |
| hsa-miR-138-5p | CTLA4 | down-regulates quantity by repression | post-transcriptional | Yes |
| ipilimumab | CTLA4 | down-regulates activity | binding | Yes |
| CTLA4 | AKT | down-regulates activity | - | No |
| CTLA4 | T cell exhaustion | up-regulates | - | No |
Section 10: Drug & Pharmacology Data ChEMBL Target Information
| Target ID | Name | Type |
|---|---|---|
| CHEMBL2364164 | Cytotoxic T-lymphocyte protein 4 | SINGLE PROTEIN |
| ChEMBL ID | Drug Name | Type | Phase | Mechanism | Key Indications |
|---|---|---|---|---|---|
| CHEMBL1789844 | Ipilimumab (Yervoy) | Antibody | 4 | CTLA-4 blocking antibody | Melanoma, RCC, NSCLC, Colorectal cancer, HCC |
| CHEMBL2108658 | Tremelimumab (Imjudo) | Antibody | 4 | CTLA-4 blocking antibody | HCC, NSCLC, Melanoma |
| CHEMBL1201823 | Abatacept (Orencia) | Protein (CTLA4-Ig fusion) | 4 | CTLA-4 mimetic (blocks CD80/CD86) | Rheumatoid arthritis, Psoriatic arthritis, JIA |
ATC Code: L01FX04
Alternative Names: BMS-734016, MDX-010, MDX-CTLA-4, Yervoy
Clinical Trials: 739
FDA-Approved Indications: Melanoma, Non-small cell lung cancer, Colorectal cancer (MSI-H), Renal cell carcinoma, Hepatocellular carcinoma, Mesothelioma Tremelimumab Clinical Details
ATC Code: L01FX20
Alternative Names: CP-675,206, Imjudo, Ticilimumab
Clinical Trials: 229
FDA-Approved Indications: Hepatocellular carcinoma (with durvalumab), Non-small cell lung cancer Abatacept Clinical Details
ATC Code: L04AA24
Alternative Names: BMS-188667, CTLA4-IGG4M, Orencia
Clinical Trials: 185
FDA-Approved Indications: Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis, GvHD prophylaxis PharmGKB Information
| Attribute | Value |
|---|---|
| PharmGKB Gene ID | PA27006 |
| VIP Gene | Yes |
| CPIC Guideline | No |
| Chromosome | chr2 |
| Drug | Clinical Annotations | Variant Annotations |
|---|---|---|
| tacrolimus | 82 | 1,120 |
| peginterferon alfa-2b | 41 | 289 |
| ribavirin | 46 | 346 |
| peginterferon alfa-2a | 31 | 211 |
| cyclosporine | 26 | 157 |
| infliximab | 21 | 128 |
| adalimumab | 18 | 118 |
| etanercept | 15 | 99 |
| dexamethasone | 14 | 55 |
| prednisone | 13 | 66 |
| rituximab | 10 | 55 |
Section 11: Expression Profiles Bgee Expression Summary
| Attribute | Value |
|---|---|
| Gene | CTLA4 (ENSG00000163599) |
| Species | Homo sapiens |
| Expression Breadth | Ubiquitous |
| Total Present Calls | 164 |
| Max Expression Score | 87.62 |
| Tissue (UBERON) | ID |
|---|---|
| Lymph node | UBERON:0000029 |
| Spleen | UBERON:0002106 |
| Thymus | UBERON:0002370 |
| Tonsil | UBERON:0002372 |
| Blood | UBERON:0000178 |
| Small intestine Peyer's patch | UBERON:0003454 |
| Bone marrow | UBERON:0002371 |
| Vermiform appendix | UBERON:0001154 |
| Caecum | UBERON:0001153 |
| Lung | UBERON:0002048 |
| Intestine | UBERON:0000160 |
| Small intestine | UBERON:0002108 |
| Large intestine | UBERON:0000059 |
| Colon | UBERON:0001155 |
| Rectum | UBERON:0001052 |
| Transverse colon | UBERON:0001157 |
| Colonic mucosa | UBERON:0000317 |
| Ileal mucosa | UBERON:0000331 |
| Liver | UBERON:0002107 |
| Gallbladder | UBERON:0002110 |
| Stomach | UBERON:0000945 |
| Esophagus | UBERON:0001043 |
| Duodenum | UBERON:0002114 |
| Placenta | UBERON:0001987 |
| Prostate gland | UBERON:0002367 |
| Testis | UBERON:0000473 |
| Uterus | UBERON:0000995 |
| Endometrium | UBERON:0001295 |
| Mammary gland | UBERON:0001911 |
| Skin | UBERON:0000014 |
| Cell Type | ID |
|---|---|
| Leukocyte | CL:0000738 |
| Granulocyte | CL:0000094 |
| Bone marrow cell | CL:0002092 |
| Buccal mucosa cell | CL:0002336 |
| Epithelial cell of pancreas | CL:0000083 |
| Pancreatic ductal cell | CL:0002079 |
| Dataset ID | Description | Cells |
|---|---|---|
| E-CURD-89 | scRNA-seq of immune cells from colon lamina propria and mesenteric lymph nodes | 1,526 |
| E-CURD-95 | EOMES+ Tr1-like cells in primary and metastatic tumors | 87,767 |
| E-HCAD-29 | GM-CSF-producing T helper cells | 78,686 |
Section 12: Disease Associations Mendelian/Monogenic Disease Links GenCC Curated Gene-Disease Associations (Total: 4)
| Disease | Disease ID | Classification | Inheritance | Submitter |
|---|---|---|---|---|
| Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | OMIM:616100 | Strong | AD | Ambry Genetics |
| Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | OMIM:616100 | Strong | AD | Labcorp Genetics |
| Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | ORPHANET:436159 | Supportive | AD | Orphanet |
| Systemic lupus erythematosus | ORPHANET:536 | Supportive | Unknown | Orphanet |
| Disease | Orphanet ID | Type | Phenotypes |
|---|---|---|---|
| Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | 436159 | Disease | 31 |
| Systemic lupus erythematosus | 536 | Disease | 44 |
| Adult-onset myasthenia gravis | 391490 | Clinical subtype | - |
| Classic mycosis fungoides | 2584 | Disease | 29 |
| Sézary syndrome | 3162 | Disease | 29 |
| Granulomatosis with polyangiitis | 900 | Disease | 80 |
| HPO ID | Phenotype |
|---|---|
| HP:0000006 | Autosomal dominant inheritance |
| HP:0002960 | Autoimmunity |
| HP:0002721 | Immunodeficiency |
| HP:0001890 | Autoimmune hemolytic anemia |
| HP:0001973 | Autoimmune thrombocytopenia |
| HP:0001904 | Autoimmune neutropenia |
| HP:0001888 | Decreased total lymphocyte count |
| HP:0001873 | Thrombocytopenia |
| HP:0001878 | Hemolytic anemia |
| HP:0002716 | Lymphadenopathy |
| HP:0001744 | Splenomegaly |
| HP:0002240 | Hepatomegaly |
| HP:0002014 | Diarrhea |
| HP:0002037 | Inflammation of the large intestine |
| HP:0100280 | Crohn's disease |
| HP:0002090 | Pneumonia |
| HP:0002206 | Pulmonary fibrosis |
| HP:0002110 | Bronchiectasis |
| HP:0002205 | Recurrent respiratory infections |
| HP:0002788 | Recurrent upper respiratory tract infections |
| HP:0002783 | Recurrent lower respiratory tract infections |
| HP:0100651 | Type I diabetes mellitus |
| HP:0000872 | Hashimoto thyroiditis |
| HP:0100646 | Thyroiditis |
| HP:0002725 | Systemic lupus erythematosus |
| HP:0001369 | Arthritis |
| HP:0005764 | Polyarticular arthritis |
| HP:0002829 | Arthralgia |
| HP:0002633 | Vasculitis |
| HP:0200029 | Vasculitis in the skin |
| HP:0000988 | Skin rash |
| HP:0001596 | Alopecia |
| HP:0000989 | Pruritus |
| HP:0001047 | Atopic dermatitis |
| HP:0000964 | Eczematoid dermatitis |
| HP:0002315 | Headache |
| HP:0001250 | Seizure |
| HP:0100653 | Optic neuritis |
| HP:0009830 | Peripheral neuropathy |
| HP:0000763 | Sensory neuropathy |
| HP:0000099 | Glomerulonephritis |
| HP:0033726 | Lupus nephritis |
| HP:0000083 | Renal insufficiency |
| HP:0001733 | Pancreatitis |
| HP:0001945 | Fever |
| HP:0012378 | Fatigue |
| HP:0001824 | Weight loss |
| HP:0002665 | Lymphoma |
| HP:0030057 | Autoimmune antibody positivity |
| HP:0020151 | Anti-dsDNA antibody positivity |
| Study | Disease/Trait | P-value | Mapped Genes |
|---|---|---|---|
| GCST007932 | Medication use (thyroid preparations) | 5×10⁻⁸⁵ | CTLA4-ICOS |
| GCST010571 | Autoimmune thyroid disease | 2×10⁻⁷⁴ | CTLA4 |
| GCST002318 | Rheumatoid arthritis | 3×10⁻²⁵ | CTLA4-ICOS |
| GCST006959 | Rheumatoid arthritis | 1×10⁻²³ | CTLA4-ICOS |
| GCST002318 | Rheumatoid arthritis | 4×10⁻²² | CTLA4-ICOS |
| GCST005536 | Type 1 diabetes | 7×10⁻²¹ | CTLA4-ICOS |
| GCST004866 | Alopecia areata | 2×10⁻²⁰ | CTLA4 |
| GCST006959 | Rheumatoid arthritis | 9×10⁻²⁰ | CTLA4-ICOS |
| GCST090013410 | Basal cell carcinoma | 2×10⁻¹⁸ | CTLA4-ICOS |
| GCST008644 | Celiac disease and RA | 2×10⁻¹⁷ | CD28 |
| GCST001200 | Graves' disease | 2×10⁻¹⁷ | CTLA4 |
| GCST001191 | Type 1 diabetes | 2×10⁻¹⁷ | CTLA4-ICOS |
| GCST009875 | Type 1 diabetes | 2×10⁻¹⁶ | CTLA4-ICOS |
| GCST009873 | Autoimmune traits (pleiotropy) | 5×10⁻¹⁶ | CTLA4-ICOS |
| GCST008871 | Basal cell carcinoma | 3×10⁻¹⁶ | CTLA4-ICOS |
| GCST000392 | Type 1 diabetes | 1×10⁻¹⁵ | CTLA4-ICOS |
| GCST003988 | Hypothyroidism | 1×10⁻¹⁵ | CTLA4-ICOS |
| GCST005523 | Celiac disease | 1×10⁻¹⁵ | CD28 |
| GCST006048 | Rheumatoid arthritis (ACPA+) | 9×10⁻¹⁵ | CTLA4-ICOS |
| GCST008870 | Keratinocyte cancer | 1×10⁻¹⁴ | CTLA4 |
| GCST000719 | Alopecia areata | 4×10⁻¹³ | CTLA4 |
| GCST004302 | Primary biliary cholangitis | 1×10⁻¹³ | NPM1P33-RNU6-474P |
| GCST009877 | Rheumatoid arthritis | 1×10⁻¹¹ | CTLA4-ICOS |
| GCST005568 | Rheumatoid arthritis (ACPA+) | 4×10⁻¹¹ | CTLA4-ICOS |
| GCST090011871 | Addison's disease | 5×10⁻¹¹ | RNU6-474P-CTLA4 |
| GCST002838 | Myasthenia gravis | 9×10⁻¹¹ | CTLA4 |
| GCST000258 | Type 1 diabetes | 8×10⁻¹¹ | CTLA4-ICOS |
| GCST005569 | Rheumatoid arthritis | 7×10⁻¹¹ | CTLA4-ICOS |
| GCST004785 | Vitiligo | 1×10⁻¹⁰ | CTLA4-ICOS |
| GCST006979 | Heel bone mineral density | 3×10⁻¹⁰ | RNU6-474P-CTLA4 |
SUMMARY STATISTICS
| Category | Count |
|---|---|
| Gene Identifiers | 5 major databases |
| Transcripts (Ensembl) | 7 |
| RefSeq mRNA | 2 |
| CCDS | 2 |
| Exons (canonical) | 4 |
| UniProt Proteins | 3 (1 reviewed) |
| InterPro Domains | 6 |
| PDB Structures | 22 |
| Orthologs | 2 (mouse, rat) |
| ClinVar Variants | 285 |
| Pathogenic/Likely Pathogenic | 41 |
| SpliceAI Predictions | 366 |
| AlphaMissense Predictions | 1,460 |
| Reactome Pathways | 3 |
| GO Terms | 19 |
| IntAct Interactions | 53 |
| STRING Interactions | 3,692 |
| BioGRID Interactions | 118 |
| ESM2 Similar Proteins | 51 |
| DIAMOND Homologs | 11 |
| Upstream TF Regulators | 15 |
| Approved Drugs (Phase 4) | 3 |
| Clinical Trials | 1,153+ |
| PharmGKB Drug Associations | 19 |
| Tissues Expressed | 100+ |
| Cell Types Expressed | 8 |
| scRNA-seq Datasets | 3 |
| GenCC Disease Associations | 4 |
| Orphanet Diseases | 6 |
| HPO Phenotypes | 189 |
| GWAS Associations | 46 |
Generated from BioBTree integrated biological database. Data current as of query date. I’ve compiled a comprehensive cross-database identifier and functional mapping reference for human CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4). This document includes: Key Highlights:
Gene: HGNC:2505 | ENSG00000163599 | Entrez 1493 | OMIM 123890
Location: Chromosome 2q33.2 (203,853,888-203,873,965, + strand)
Protein: P16410 (UniProt, 223 amino acids)
Structures: 22 experimental PDB structures (mostly antibody complexes)
Variants: 285 ClinVar entries (41 pathogenic/likely pathogenic)
Approved Drugs: Ipilimumab, Tremelimumab (CTLA-4 blockers), Abatacept (CTLA4-Ig fusion)
Key Diseases: ALPS due to CTLA4 haploinsufficiency, plus strong GWAS associations with autoimmune thyroid disease, rheumatoid arthritis, type 1 diabetes, alopecia areata, celiac disease, and multiple cancers
Interactions: 3,692 STRING interactions; key partners include CD80, CD86, CD28, PD-1, ICOS
Expression: Ubiquitous but highest in lymphoid tissues (lymph nodes, spleen, thymus, tonsils) This reference document serves as a definitive lookup resource covering all 12 requested sections with complete identifier mappings and functional annotations.